CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer
Status:
Completed
Trial end date:
2017-10-04
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the efficacy of CetuGEX™ for the treatment of patients
with stage III/IV recurrent and/or metastatic SCCHN as compared to cetuximab (both in
combination with platinum-based chemotherapy) in terms of progression-free survival (PFS).